1Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer, 2001,2:129-135.
2Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol, 1999,17:2639-2648.
3Lee S, Yang W, Lan KH, et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res, 2002,62:5703-5710.
4Slamon DJ, Jones BL, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344:783-792.
5Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol, 2003,21:46-53.
6Jones BL. Trastuzumab: hopes and realities. The Lancet Oncol,2002,3: 137-144.
7Pienkowski T, Fumoleau P, Eiermann W, et al. Taxotere, cisplatin and herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase Ⅱ pilot study by the breast cancer international research group. Proc Am Soc Clin Oncol, 2001,20: 70b.
8Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology, 2002,63 Suppl 1:57-63.
3Corbett TH, Griswold DP, Roberts B J, et al. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy [J]. Cancer Treat Rep, 1978, 62(10) :1471-1488.
4Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotberapy on kunetics and growth of metastases[J]. Cancer Res, 1983, 43 (4) : 1488- 1492.
5Mamounes EP, Wang J, Bryant J, et al. Patterns of loco-regional failure (LRF') in patients receiving neoadjuvant chemotherapy (NC) : results from NSABP B-I8 [ J ]. Breast Cancer Res Treat, 2003, 82 ( Suppl 1 ) : 17.
6Canoe WG, Carey IA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservating and predicts outstanding local control and survival[ J]. Am Surg, 2002, 236 (3) :295.
7Levin MN, Bramwell VH, Pritchhard KI, et al. Randomized trail of intensive eyelophosphamide. Methorxale, and fluorouracil inpremenopansal women with node positive breast cancer. National cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 1998, 16(8):2651-2658.
8Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in post menopausal women : results from the more randomized trial[J]. Multiple Outcomes of Raloxifene Evaluation [ J 1. JAMA, 1999,16 (23) :2189.
9Lohrisch C, Piccar M. HER2/neu as a predictive factor in breast cancer[ J]. Clin Breast Cancer, 2001, 2:129-135.
10Michaud LB, Valero Y, Hortobagyi C. Risks and benefits of taxanxes in breast and ovarian cancer [ J ]. Drug Safety, 2000, 23 (5) :401-428.
